Esperion Therapeutics Stock (NASDAQ: ESPR)

Esperion Therapeutics Stock (NASDAQ:ESPR), Trade Ideas

Esperion Therapeutics

Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.

News

Penny Stocks

Small Cap

Pre-Market Outlook

Markets

Movers

Trading Ideas

APLD

ESPR

NRIX

TSHA

TVGN

XPEV

U.S. stock futures were lower this morning, with the Dow futures falling over 50 points on Friday.

Applied Digital Reports Downbeat Results, Joins Nurix Therapeutics And Other Big Stocks Moving Lower In Friday&#39;s Pre-Market Session

Intraday Update

ACOR

AKAN

ALPN

ANAB

APVO

CADL

CLRO

ELVN

ELYM

ENLV

FAST

GYRE

ICCT

JANX

LOVE

MRIN

NKLA

NYXH

RCEL

RENT

RLYB

SLNA

SPRC

STEP

SUUN

VBIV

VERB

Shares of  Fastenal Company (NASDAQ: FAST) fell sharply during Thursday’s session following worse-than-expected first-quarter financial results.

Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday&#39;s Mid-Day Session

AEHL

ALLR

AUUD

BCAN

BRCC

CCTG

DXYZ

EPRX

FAAS

FLGC

GLMD

LGVN

MDIA

MSTR

NCPL

RELI

XXII

ZOOZ

Shares of  Esperion Therapeutics, Inc.  (NASDAQ: ESPR) shares rose sharply during today’s pre-market trading after the company presented new data from CLEAR outcomes at ACC.24 highlighting value of NEXLETOL® tablets in diverse populations.

Why Esperion Therapeutics Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket

Esperion Therapeutics, Inc. - Common Stock

Esperion Therapeutics Inc

ESPRIT HOLDINS LTD by Esprit Holdings Ltd.

Esprit Holdings Ltd

ESPRIT HLDGS S/ADR by Esprit Holdings Ltd.

U.S. stock futures were lower this morning, with the Dow futures falling over 50 points on Friday.
Shares of Applied Digital Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/apld#NASDAQ">APLD</a>) fell sharply in today&rsquo;s pre-market trading after the company reported worse-than-expected <a href="https://www.benzinga.com/quote/APLD/earnings">third-quarter financial results</a>.
Applied Digital posted a quarterly loss of 24 cents per share, versus a year-ago loss of 10 cents per share. The company&rsquo;s quarterly sales came in at $43.35 million versus expectations of $51.92 million, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro.</a>
Applied Digital shares dipped 9.1% to $2.79 in pre-market trading.
Here are some big stocks recording losses in today&rsquo;s pre-market trading session.
<ul>
<li>Tevogen Bio Holdings Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tvgn#NASDAQ">TVGN</a>) shares declined 8.5% to $2.26 in pre-market trading.</li>
<li>Nurix Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nrix#NASDAQ">NRIX</a>) shares declined 6.3% to $16.12 pre-market trading after the company priced its upsized $175m public offering of 10,166,667 common shares at $15 per share.</li>
<li>XPeng Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/xpev#NYSE">XPEV</a>) shares fell 4.6% to $7.89 in pre-market trading.</li>
<li>Taysha Gene Therapies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tsha#NASDAQ">TSHA</a>) shares fell 3.7% to $3.10 in pre-market trading.</li>
<li>Korea Electric Power Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/kep#NYSE">KEP</a>) shares declined 3.2% to $7.54 in pre-market trading after falling over 3% on Thursday.</li>
<li>Esperion Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/espr#NASDAQ">ESPR</a>) shares fell 3.1% to $2.24 in pre-market trading after dipping 8% on Thursday.</li>
<li>JD.com, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/jd#NASDAQ">JD</a>) shares fell 3% to $26.20 in pre-market trading.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/news/earnings/24/04/38215285/citigroup-jpmorgan-and-3-stocks-to-watch-heading-into-friday"> Citigroup, JPMorgan And 3 Stocks To Watch Heading Into Friday </a>
Don&rsquo;t forget to check out our <a href="https://www.benzinga.com/premarket/"> premarket coverage here </a>

Applied Digital Reports Downbeat Results, Joins Nurix Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market Session

Shares of Fastenal Company (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/fast#NASDAQ">FAST</a>) fell sharply during Thursday&rsquo;s session following worse-than-expected first-quarter financial results.
Fastenal reported first-quarter FY24 sales growth of 1.9% Y/Y to $1.895 billion, missing the consensus of $1.914 billion. The company&#39;s first-quarter EPS was 52 cents, missing the consensus of 53 cents.
Fastenal shares dipped 6.7% to $69.73 on Thursday.
Here are some other stocks moving in today&#39;s mid-day session.
<h3>Gainers</h3>
<ul>
<li>Rallybio Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rlyb#NASDAQ">RLYB</a>) shares climbed 89.6% to $3.09 after the company announced a collaboration with Johnson &amp; Johnson to advance therapeutics for pregnant individuals at risk of FNAIT.</li>
<li>Rent the Runway, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rent#NASDAQ">RENT</a>) shares jumped 74.5% to $12.91 after the company reported mixed fourth-quarter financial results and issued guidance.</li>
<li>Eliem Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/elym#NASDAQ">ELYM</a>) jumped 59.6% to $4.2650. The company announced that it entered into a definitive acquisition agreement to acquire Tenet and it also entered into a securities purchase agreement for a $120 million private placement.</li>
<li>Akanda Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/akan#NASDAQ">AKAN</a>) gained 36% to $0.1632. Akanda, last month, announced a plan to evaluate opportunities in Bitcoin, Blockchain and AI applications in the cannabis industry.</li>
<li>Alpine Immune Sciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/alpn#NASDAQ">ALPN</a>) rose 36.6% to $64.25 after Vertex entered into an agreement to acquire the company.</li>
<li>Candel Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cadl#NASDAQ">CADL</a>) surged 29.6% to $6.61 after the company received FDA orphan drug designation for CAN-2409 for the treatment of pancreatic cancer.</li>
<li>Enliven Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/elvn#NASDAQ">ELVN</a>) gained 26% to $24.97. Enliven Therapeutics announced proof of concept data from Phase 1 clinical trial of ELVN-001 in chronic myeloid leukemia.</li>
<li>Selina Hospitality PLC (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/slna#NASDAQ">SLNA</a>) rose 21.1% to $0.0923.</li>
<li>Globavend Holdings Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gvh#NASDAQ">GVH</a>) climbed 16.8% to $1.68.</li>
<li>Janux Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/janx#NASDAQ">JANX</a>) gained 16.8% to $52.15 following Wednesday reports suggesting the company is said to weigh a possible sale.</li>
<li>SciSparc Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sprc#NASDAQ">SPRC</a>) shares rose 15.3% to $1.9357.</li>
<li>Gyre Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gyre#NASDAQ">GYRE</a>) gained 14.6% to $15.91.</li>
<li>AnaptysBio, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/anab#NASDAQ">ANAB</a>) climbed 11.4% to $24.72. Wells Fargo analyst Derek Archila initiated coverage on AnaptysBio with an Overweight rating and announced a price target of $56.</li>
<li>Verb Technology Company, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/verb#NASDAQ">VERB</a>) gained 10.4% to $0.2010 after gaining 4% on Wednesday.</li>
<li>GigaCloud Technology Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gct#NASDAQ">GCT</a>) rose 10.2% to $34.18.</li>
<li>Nurix Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nrix#NASDAQ">NRIX</a>) gained 9.6% to $17.21. Baird analyst Joel Beatty maintained Nurix Therapeutics with an Outperform and raised the price target from $24 to $25.</li>
<li>StepStone Group LP (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/step#NASDAQ">STEP</a>) rose 7.1% to $37.46 after JP Morgan upgraded the stock from Neutral to Overweight.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>Aptevo Therapeutics Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/apvo#NASDAQ">APVO</a>) shares fell 58% to $1.01 after the company priced its $4.6 million public offering.</li>
<li>Enlivex Therapeutics Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/enlv#NASDAQ">ENLV</a>) fell 54.5% to $1.81. The company announced topline results of its Phase II trial evaluating Allocetra in sepsis.</li>
<li>AVITA Medical, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rcel#NASDAQ">RCEL</a>) fell 28.6% to $10.31 after the company announced an update to its expected commercial revenue for the first quarter of 2024. BTIG downgraded the stock from Buy to Neutral.</li>
<li>Aesthetic Medical International Holdings Group Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aih#NASDAQ">AIH</a>) fell 19% to $0.3723.</li>
<li>Globe Life Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/gl#NYSE">GL</a>) fell 14.6% to $89.65.</li>
<li>The Lovesac Company (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/love#NASDAQ">LOVE</a>) shares fell 14.3% to $20.00 after the company reported worse-than-expected fourth-quarter results and issued first-quarter guidance.</li>
<li>Globe Life Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/gl#NYSE">GL</a>) fell 13.7% to $90.56.</li>
<li>Meiwu Technology Company Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/wnw#NASDAQ">WNW</a>) shares declined 12.4% to $1.1601 after jumping around 32% on Wednesday.</li>
<li>Acorda Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/acor#NASDAQ">ACOR</a>) fell 12% to $0.7660 after declining 14% on Wednesday. Acorda Therapeutics recently commenced voluntary proceedings under Chapter 11 of the United States Bankruptcy Code.</li>
<li>CarMax, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/kmx#NYSE">KMX</a>) fell 11.7% to $70.02 after the company reported lower-than-expected fourth-quarter earnings.</li>
<li>VBI Vaccines Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vbiv#NASDAQ">VBIV</a>) dipped 11.3% to $0.5641.</li>
<li>Nikola Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nkla#NASDAQ">NKLA</a>) fell 11.3% to $0.8680. On April 9, Wolfe Research analyst Scott Group initiated coverage on Nikola with a Peer Perform rating.</li>
<li>Marin Software Incorporated (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mrin#NASDAQ">MRIN</a>) declined 10.8% to $0.5798.</li>
<li>SolarBank Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/suun#NASDAQ">SUUN</a>) fell 9.3% to $5.29. SolarBank closed purchase of 3.15 MW solar project in New York from Storke Renewable.</li>
<li>Esperion Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/espr#NASDAQ">ESPR</a>) fell 9.1% to $2.29.</li>
<li>9F Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/jfu#NASDAQ">JFU</a>) fell 8.8% to $2.7046.</li>
<li>iCoreConnect Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/icct#NASDAQ">ICCT</a>) shares fell 8.5% to $1.55 after jumping over 50% on Wednesday.</li>
<li>ClearOne, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/clro#NASDAQ">CLRO</a>) declined 8.3% to $1.00. The company recently reported fourth-quarter financial results.</li>
<li>Nyxoah S.A. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nyxh#NASDAQ">NYXH</a>) fell 7.3% to $9.83</li>
<li>Acorda Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/acor#NASDAQ">ACOR</a>) fell 6.2% to $0.8164.</li>
<li>Walker &amp; Dunlop, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/wd#NYSE">WD</a>) fell 5.3% to $87.71 after Wedbush downgraded the stock from Outperform to Neutral and lowered its price target from $130 to $95.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/04/38200890/top-3-health-care-stocks-which-could-rescue-your-portfolio-this-quarter"> Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Quarter</a>

Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

Needham analyst Serge Belanger reiterates Esperion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESPR#NASDAQ">ESPR</a>) with a Buy and maintains $8 price target.

Price Target

Reiteration

Analyst Ratings

Needham Reiterates Buy on Esperion Therapeutics, Maintains $8 Price Target

WIIM

Esperion Therapeutics shares are trading lower. The company announced the presentation of new data from CLEAR Outcomes.

Shares of Esperion Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/espr#NASDAQ">ESPR</a>) shares rose sharply during today&rsquo;s pre-market trading after the company presented new data from CLEAR outcomes at ACC.24 highlighting value of NEXLETOL&reg; tablets in diverse populations.
Esperion Therapeutics shares climbed 7.1% to $3.47 pre-market trading.
Here are some other stocks moving in pre-market trading.
<h3>Gainers</h3>
<ul>
<li>Longeveron Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lgvn#NASDAQ">LGVN</a>) rose 93.2% to $4.25 in pre-market trading after gaining 8% on Friday.</li>
<li>Antelope Enterprise Holdings Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aehl#NASDAQ">AEHL</a>) shares rose 47% to $2.20 in pre-market trading after declining 5% on Friday. On April 1, Antelope Enterprise announced preliminary full year 2023 revenue of $70.4 million.</li>
<li>DigiAsia Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/faas#NASDAQ">FAAS</a>) shares rose 31.6% to $8.46 in pre-market trading after the jumping around 17% on Friday.</li>
<li>BYND Cannasoft Enterprises Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bcan#NASDAQ">BCAN</a>) gained 27.2% to $1.31 in pre-market trading.</li>
<li>Allarity Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/allr#NASDAQ">ALLR</a>) gained 25.6% to $0.2840 in pre-market trading after dipping over 8% on Friday. The company, last week, announced a 1-for-20 reverse stock split.</li>
<li>Auddia Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/auud#NASDAQ">AUUD</a>) shares gained 15.4% to $1.65 in pre-market trading after declining around 5% on Friday.</li>
<li>Galmed Pharmaceuticals Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/glmd#NASDAQ">GLMD</a>) rose 15% to $0.39 in pre-market trading. Last week, Galmed Pharmaceuticals filed annual report on Form 20-F for the fiscal year ended Dec. 31, 2023.</li>
<li>Destiny Tech100 Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dxyz#NASDAQ">DXYZ</a>) climbed 10.3% to $65.36 in pre-market trading after jumping around 77% on Friday.</li>
<li>MicroStrategy Incorporated (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mstr#NASDAQ">MSTR</a>) gained 9.4% to $1,573.93 in pre-market trading amid a rise in Bitcoin.</li>
</ul>
<h3>
Losers</h3>
<ul>
<li>22nd Century Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/xxii#NASDAQ">XXII</a>) declined 22.4% to $2.76 in pre-market trading. 22nd Century Group shares jumped over 140% on Friday after the company signed a new contract manufacturing agreement for the production of branded conventional cigarette products.</li>
<li>MediaCo Holding Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mdia#NASDAQ">MDIA</a>) fell 18.8% to $3.15 in pre-market trading. Shares of MediaCo Holding jumped 177% on Friday after a 13D amended filing showed Standard General L.P. reported a 95.2% stake in the company as of April 1, 2024.</li>
<li>Flora Growth Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/flgc#NASDAQ">FLGC</a>) fell 15.1% to $2.02 in pre-market trading.</li>
<li>Flora Growth, last week, reported the pricing of its underwritten public offering of 1.7 million common shares for aggregate gross proceeds of roughly $3.23 million.</li>
<li>ZOOZ Power Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/zooz#NASDAQ">ZOOZ</a>) fell 14.5% to $3.50 in pre-market trading.</li>
<li>Netcapital Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ncpl#NASDAQ">NCPL</a>) fell 13.5% to $0.1064 pre-market trading after declining over 6% on Friday.</li>
<li>&nbsp;</li>
<li>Globavend Holdings Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gvh#NASDAQ">GVH</a>) shares fell 11% to $1.46 in pre-market trading after jumping 57% on Friday.</li>
<li>CCSC Technology International Holdings Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cctg#NASDAQ">CCTG</a>) shares fell 8% to $3.11 in pre-market trading after surging around 28% on Friday.</li>
<li>BRC Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/brcc#NYSE">BRCC</a>) shares declined 7.8% to $4.38 in pre-market trading after surging over 5% on Friday.</li>
<li>Reliance Global Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/reli#NASDAQ">RELI</a>) fell 6.8% to $0.4523 pre-market trading. Reliance Global, last week, reported FY23 earnings.</li>
<li>Eupraxia Pharmaceuticals Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/eprx#NASDAQ">EPRX</a>) fell 5.1% to $2.80 in pre-market trading.</li>
</ul>

Now Read This: <a href="https://www.benzinga.com/news/earnings/24/04/38136246/radcom-lotus-technology-and-3-stocks-to-watch-heading-into-monday"> RADCOM, Lotus Technology And 3 Stocks To Watch Heading Into Monday</a>

Patients With Obesity Who Took NEXLETOL Were&nbsp;23%&nbsp;Less Likely to Experience a Major Adverse Cardiovascular Event (MACE-4) Compared to Placebo 
	NEXLETOL Demonstrated Clinical Benefit in Historically
<ul>
<li>Patients With Obesity Who Took NEXLETOL Were&nbsp;23%&nbsp;Less Likely to Experience a Major Adverse Cardiovascular Event (MACE-4) Compared to Placebo</li>
<li>NEXLETOL Demonstrated Clinical Benefit in Historically Underrepresented Groups: Women and Hispanic/Latinx Patients With and Without Cardiovascular Disease (CVD)</li>
<li>CLEAR Outcomes Sets New Standards for Diversity and Inclusion with Enrollment of&nbsp;48%&nbsp;Women and&nbsp;17%&nbsp;Hispanic/Latinx Patients</li>
</ul>

Reported Sunday, Esperion Presents New Data From CLEAR Outcomes At ACC.24 Highlighting Value Of NEXLETOL® Tablets In Diverse Populations

Shares of Ulta Beauty, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ulta#NASDAQ">ULTA</a>) fell sharply during Wednesday&rsquo;s session amid the company&#39;s presentation at the J.P. Morgan Retail Roundup investor conference where the company reportedly issued a weak outlook.
Ulta Beauty shares dipped 13.7% to $448.08 on Wednesday.
Here are some other stocks moving in today&#39;s mid-day session.
<h3>Gainers</h3>
<ul>
<li>ARCA biopharma, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/abio#NASDAQ">ABIO</a>) climbed 108% to $3.5549 after the company and Oruka Therapeutics announced a merger agreement.</li>
<li>Kintara Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ktra#NASDAQ">KTRA</a>) shares gained 89% to $0.1906 after the company entered a merger agreement with TuHURA Biosciences.</li>
<li>Next Technology Holding Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nxtt#NASDAQ">NXTT</a>) rose 57.4% to $6.42.</li>
<li>Vanda Pharmaceuticals Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vnda#NASDAQ">VNDA</a>) shares climbed 39.3% to $5.45. Vanda Pharmaceuticals&#39; Fanapt&reg; received U.S. FDA approval for the acute treatment of Bipolar I Disorder.</li>
<li>VivoPower International PLC (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vvpr#NASDAQ">VVPR</a>) shares gained 39% to $8.20 after the company declared a capital management strategy including a stock buyback program of up to $5 million.</li>
<li>Next.e.GO N.V. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/egox#NASDAQ">EGOX</a>) gained 32.7% to $0.0345.</li>
<li>XTI Aerospace, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/xtia#NASDAQ">XTIA</a>) rose 32.2% to $4.63. BestGrowthStocks.com issued comprehensive evaluation of XTI Aerospace, Inc.</li>
<li>Brooge Energy Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/brog#NASDAQ">BROG</a>) gained 28.8% to $3.0790.</li>
<li>Addex Therapeutics Ltd (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/adxn#NASDAQ">ADXN</a>) rose 24.6% to $16.21 after the company and funds affiliated with Perceptive Advisors announced the launch of Neurosterix.</li>
<li>Aesthetic Medical International Holdings Group Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aih#NASDAQ">AIH</a>) gained 24.3% to $0.3981 after gaining 13% on Tuesday.</li>
<li>LAMF Global Ventures Corp. I (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lgvc#NASDAQ">LGVC</a>) gained 22.7% to $13.21. ViewLAMF Global Ventures Corp. I shareholders approved previously announced business combination with Nuvo Group Ltd.</li>
<li>Quhuo Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/qh#NASDAQ">QH</a>) rose 21.7% to $0.6501 after reporting unaudited financial results for the second half and full year 2023.</li>
<li>Destiny Tech100 Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dxyz#NYSE">DXYZ</a>) gained 21.4% to $25.77.</li>
<li>OneMedNet Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/onmd#NASDAQ">ONMD</a>) gained 21.2% to $0.9600. OneMedNet announced it entered a securities purchase agreement dated Mar. 28 providing up to $4.54 million in funding through private placement of senior convertible notes.</li>
<li>CXApp Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cxai#NASDAQ">CXAI</a>) gained 20.5% to $5.40 following a massive rally to start the week. CXApp shares rallied more than 150% to start the week after the company announced a partnership with Alphabet&rsquo;s Google Cloud.</li>
<li>Clean Energy Technologies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cety#NASDAQ">CETY</a>) climbed 20.5% to $1.63.</li>
<li>American Battery Technology Company (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/abat#NASDAQ">ABAT</a>) rose 17.7% to $1.9301. American Battery Technology Company was awarded $20 million tax credit through competitive U.S. DOE process to advance its critical minerals battery recycling facility.</li>
<li>C3is Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ciss#NASDAQ">CISS</a>) shares rose 14.9% to $0.0470 after gaining 13% on Tuesday. On March 26, C3is reported a year-over-year increase in fourth-quarter financial results.</li>
<li>Pyxis Oncology, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pyxs#NASDAQ">PYXS</a>) gained 12.3% to $6.04.</li>
<li>Atai Life Sciences N.V. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/atai#NASDAQ">ATAI</a>) surged 11.4% to $2.08. Maxim Group analyst Jason McCarthy upgraded ATAI Life Sciences from Hold to Buy and announced a $6 price target.</li>
<li>Dave &amp; Buster&#39;s Entertainment, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/play#NASDAQ">PLAY</a>) shares rose 10.2% to $68.22 after the company reported fourth quarter results.</li>
<li>Esperion Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/espr#NASDAQ">ESPR</a>) jumped 9.7% to $3.16.</li>
<li>Signet Jewelers Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/sig#NYSE">SIG</a>) gained 9.2% to $103.80after the company raised its FY25 guidance.</li>
<li>Inspire Veterinary Partners, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ivp#NASDAQ">IVP</a>) gained 9% to $0.0512. On Jan. 5, Inspire Veterinary Partners filed a prospectus related to up to a $5 million public offering.</li>
<li>Semtech Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/smtc#NASDAQ">SMTC</a>) gained 7.4% to $30.28.</li>
<li>Cal-Maine Foods, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/calm#NASDAQ">CALM</a>) climbed 6.8% to $62.88 after the company reported upbeat results for its fourth quarter.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>Casa Systems, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/casa#NASDAQ">CASA</a>) shares dipped 78.1% to $0.0563 after the Company filed voluntary petitions for relief under Chapter 11 of the Bankruptcy Code in the U.S. Bankruptcy Court.</li>
<li>View, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/view#NASDAQ">VIEW</a>) fell 61.9% to $0.4196 after the company filed for Chapter 11 bankruptcy. The company on Tuesday said it reached a real with Cantor Fitzgerald and RXR to become a private company.</li>
<li>Sintx Technologies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sint#NASDAQ">SINT</a>) fell 44.5% to $0.0232 after the company announced pricing of a $1.5 million public offering of common stock.</li>
<li>GCT Semiconductor Holding, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/gcts#NYSE">GCTS</a>) dipped 40% to $9.29 amid volatility following the company&#39;s recently completed business combination with Concord Acquisition Corp III and NYSE debut.</li>
<li>FibroGen, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/fgen#NASDAQ">FGEN</a>) fell 32.8% to $1.4499. FibroGen announced topline data from the Fortis Therapeutics-sponsored Phase 1 study of FG-3246 (also known as FOR46), a potential first-in-class anti-CD46 antibody drug conjugate (ADC) with an MMAE-containing payload.</li>
<li>Keyarch Acquisition Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/kych#NASDAQ">KYCH</a>) fell 28.5% to $9.65.</li>
<li>TRACON Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tcon#NASDAQ">TCON</a>) dipped 24.2% to $0.3148 as the company issued an update on ongoing ENVASARC Phase 2 pivotal trial following Independent Data Monitoring Committee Recommendation to continue the trial as planned.</li>
<li>BYND Cannasoft Enterprises Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bcan#NASDAQ">BCAN</a>) fell 22.5% to $0.9741 after dipping around 12% on Tuesday.</li>
<li>Anghami Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/angh#NASDAQ">ANGH</a>) fell 22.2% to $1.40. Anghami recently announced that it completed its transaction with OSN+.</li>
<li>Locafy Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lcfy#NASDAQ">LCFY</a>) dipped 21.9% to $3.67 following second-quarter results.</li>
<li>Vicinity Motor Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vev#NASDAQ">VEV</a>) fell 19.3% to $0.75 after the company reported a year-over-year decrease in fourth-quarter EPS results.</li>
<li>Enveric Biosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/envb#NASDAQ">ENVB</a>) dipped 18.4% to $0.93.</li>
<li>Murano Global Investments Plc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mrno#NASDAQ">MRNO</a>) fell 16.8% to $10.39.</li>
<li>Critical Metals Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/crml#NASDAQ">CRML</a>) fell 16.7% to $11.66.</li>
<li>Acorda Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/acor#NASDAQ">ACOR</a>) shares fell 12% to $2.20. Acorda Therapeutics shares dipped 81% on Tuesday after the company commenced voluntary proceedings under Chapter 11 of the United States Bankruptcy Code.</li>
<li>Exscientia plc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/exai#NASDAQ">EXAI</a>) fell 10.8% to $4.6395 following quarterly results.</li>
<li>Gamida Cell Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gmda#NASDAQ">GMDA</a>) shares fell 8.4% to $0.0403 after gaining 18% on Tuesday.</li>
<li>e.l.f. Beauty, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/elf#NYSE">ELF</a>) fell 8.2% to $170.71 after peer Ulta Beauty reportedly issued weak guidance at a conference.</li>
<li>NWTN Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nwtn#NASDAQ">NWTN</a>) fell 8% to $7.21.</li>
<li>Mesoblast Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/meso#NASDAQ">MESO</a>) shares tumbled 7.3% to $6.11 after gaining 8% on Tuesday.</li>
<li>Applied Digital Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/apld#NASDAQ">APLD</a>) fell 6.1% to $3.5850.</li>
<li>Lands&#39; End, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/le#NASDAQ">LE</a>) fell 6.1% to $11.25.</li>
<li>Intel Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/intc#NASDAQ">INTC</a>) fell 6.1% to $41.27 after the company outlined a new financial framework for its foundry business. After the market close on Tuesday, Intel announced a new financial reporting structure designed to drive increased cost discipline and higher returns by providing greater transparency, accountability and incentives across the business.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38069445/ethereum-trades-below-3-400-following-adp-report-stacks-becomes-top-loser"> Ethereum Trades Below $3,400 Following ADP Report; Stacks Becomes Top Loser</a>

ABAT

ABIO

ADXN

ANGH

ATAI

BROG

CALM

CASA

CETY

CISS

CRML

CXAI

EGOX

ENVB

EXAI

FGEN

GCTS

GMDA

INTC

Kintara Therapeutics, Inc. - Common Stock

KTRA

KYCH

LCFY

LGVC

MESO

MRNO

NWTN

Next Technology Holding Inc. - Ordinary Shares

NXTT

ONMD

PLAY

PYXS

SINT

SMTC

TCON

ULTA

VIEW

VNDA

VVPR

XTIA

Why Ulta Beauty Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

U.S. stocks were higher, with the Dow Jones gaining over 50 points on Wednesday.
Shares of Signet Jewelers Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/sig#NYSE">SIG</a>) rose sharply during Wednesday&rsquo;s session after the company <a href="https://www.benzinga.com/markets/equities/24/04/38068195/whats-going-on-with-signet-jewelers-stock-today">raised its FY25 guidance.</a>
The company and Leonard Green &amp; Partners, L.P., an equity investment firm, today announced the amendment of the terms of the Series A Convertible Preference Shares to net share settlement and the repurchase of half of the Preferred Shares. 
Signet increased its FY25 adjusted EPS outlook to $9.90 &ndash; $11.52 from $9.08 &ndash; $10.48 versus an estimate of $9.72.
Signet Jewelers shares surged 9.2% to $103.80 on Wednesday.
Here are some other big stocks recording gains in today&rsquo;s session.
<ul>
<li>Destiny Tech100 Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dxyz#NYSE">DXYZ</a>) shares jumped 21.4% to $25.77.</li>
<li>Ocugen, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ocgn#NASDAQ">OCGN</a>) shares gained 14.2% to $1.5750. HC Wainwright &amp; Co. analyst Swayampakula Ramakanth reiterated Ocugen with a Buy and maintained a $7 price target.</li>
<li>Pyxis Oncology, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pyxs#NASDAQ">PYXS</a>) rose 12.3% to $6.04.</li>
<li>Atai Life Sciences N.V. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/atai#NASDAQ">ATAI</a>) climbed 11.4% to $2.08. Maxim Group analyst Jason McCarthy upgraded ATAI Life Sciences from Hold to Buy and announced a $6 price target.</li>
<li>SolarMax Technology, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/smxt#NASDAQ">SMXT</a>) rose 10.4% to $11.85.</li>
<li>Dave &amp; Buster&#39;s Entertainment, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/play#NASDAQ">PLAY</a>) shares gained 10.2% to $68.22 after the company reported fourth quarter results.</li>
<li>Esperion Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/espr#NASDAQ">ESPR</a>) gained 9.7% to $3.16.</li>
<li>TransMedics Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tmdx#NASDAQ">TMDX</a>) rose 9.2% to $79.47.</li>
<li>Porch Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/prch#NASDAQ">PRCH</a>) gained 8.3% to $4.3450. Cantor Fitzgerald analyst Josh Siegler maintained Porch Group with an Overweight and raised the price target from $3 to $5.</li>
<li>ZIM Integrated Shipping Services Ltd. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/zim#NYSE">ZIM</a>) gained 7.7% to $10.95.</li>
<li>Semtech Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/smtc#NASDAQ">SMTC</a>) climbed 7.4% to $30.28.</li>
<li>Cal-Maine Foods, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/calm#NASDAQ">CALM</a>) shares gained 6.8% to $62.88 after the company reported upbeat results for its fourth quarter.</li>
<li>Glaukos Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/gkos#NYSE">GKOS</a>) rose 6.8% to $95.59. Glaukos received permanent J-code for iDose&reg; TR (travoprost intracameral implant).</li>
<li>Blue Owl Capital Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/owl#NYSE">OWL</a>) gained 6.4% to $19.69 after the company announced a purchase agreement to acquire Kuvare Insurance Services LP for $750 million.</li>
<li>B. Riley Financial, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rily#NASDAQ">RILY</a>) rose 6.3% to $23.88.</li>
<li>U.S. Silica Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/slca#NYSE">SLCA</a>) gained 6.2% to $13.47.</li>
<li>Spotify Technology S.A. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/spot#NYSE">SPOT</a>) rose 5.6% to $284.61 on reports the company will raise monthly prices.</li>
<li>Arcadium Lithium plc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/altm#NASDAQ">ALTM</a>) gained 4.8% to $4.34. Raymond James upgraded the stock from Outperform to Strong Buy and maintained its $9 price target.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/news/earnings/24/04/38062892/how-to-earn-500-a-month-from-levi-strauss-stock-ahead-of-q1-earnings-report"> How To Earn $500 A Month From Levi Strauss Stock Ahead Of Q1 Earnings Report</a>

ALTM

GKOS

OCGN

PRCH

RILY

SLCA

SMXT

SPOT

TMDX

Signet Jewelers, Dave & Buster's Entertainment, Blue Owl Capital And Other Big Stocks Moving Higher On Wednesday

Biotech

General

Esperion Announces Data from CLEAR Outcomes Sub-Groups as Poster Presentations, Moderated Session & Industry Expert Theatre To Be Presented At ACC.24

Shares of Landos Biopharma, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/labp#NASDAQ">LABP</a>) rose sharply during Monday&rsquo;s session following acquisition news.
AbbVie Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/abbv#NYSE">ABBV</a>) and Landos Biopharma, reported a definitive agreement under which AbbVie will acquire Landos.
Landos Biopharma shares jumped 171.2% to $21.70 on Monday.
Here are some other stocks moving in today&#39;s mid-day session.
<h3>Gainers</h3>
<ul>
<li>Next.e.GO N.V. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/egox#NASDAQ">EGOX</a>) shares jumped 85.8% to $0.0730 after falling around 22% on Friday.</li>
<li>Altamira Therapeutics Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cyto#NASDAQ">CYTO</a>) shares climbed 70.1% to $2.9255 after the company announced a collaboration with Univercells Group on nanoparticle-delivered mRNA vaccines.</li>
<li>MicroAlgo Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mlgo#NASDAQ">MLGO</a>) climbed 34.3% to $5.40 after declining around 5% on Friday.</li>
<li>XTL Biopharmaceuticals Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/xtlb#NASDAQ">XTLB</a>) gained 32.4% to $3.4690. XTL Biopharmaceuticals recently entered into a binding term sheet to acquire all of the issued and outstanding share capital of Social Proxy.</li>
<li>Nkarta, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nktx#NASDAQ">NKTX</a>) gained 23.3% to $11.00 after the company priced $240 million underwritten offering.</li>
<li>Target Hospitality Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/th#NASDAQ">TH</a>) jumped 21.3% to $10.82 after the company received a buyout offer from TDR Capital.</li>
<li>Swvl Holdings Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/swvl#NASDAQ">SWVL</a>) rose 21.2% to $11.26.</li>
<li>Brainstorm Cell Therapeutics Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bcli#NASDAQ">BCLI</a>) surged 21% to $0.6949.</li>
<li>Lucid Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lcid#NASDAQ">LCID</a>) jumped 18.7% to $3.29 after the company announced a $1 billion investment by an affiliate of PIF.</li>
<li>Sagimet Biosciences Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sgmt#NASDAQ">SGMT</a>) rose 16.9% to $5.27 after the company reported FY results and announced the appointment of Tim Walbert and Paul Hoelscher to its Board of Director.</li>
<li>Ocugen, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ocgn#NASDAQ">OCGN</a>) jumped 16.4% to $1.9101. The Third Circuit Court of Appeals recently upheld the decision of the Eastern District of Pennsylvania to dismiss with prejudice the consolidated securities class action lawsuits against Ocugen.</li>
<li>Flora Growth Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/flgc#NASDAQ">FLGC</a>) shares gained 15.2% to $1.8206 after surging around 34% on Friday.</li>
<li>Forge Global Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/frge#NYSE">FRGE</a>) shares gained 14.5% to $2.67 after gaining 13% on Friday.</li>
<li>Cipher Mining Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cifr#NASDAQ">CIFR</a>) jumped 14.1% to $5.27.</li>
<li>GoodRx Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gdrx#NASDAQ">GDRX</a>) rose 13.5% to $7.44 after Wells Fargo upgraded the stock from Equal-Weight to Overweight and announced a $10 price target.</li>
<li>Neuronetics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/stim#NASDAQ">STIM</a>) climbed 13.5% to $4.80. NeuroStar&reg; Advanced Therapy received FDA clearance as a first-line add-on treatment for adolescents with depression.</li>
<li>Lichen China Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/licn#NASDAQ">LICN</a>) rose 12.6% to $1.16. Lichen China announced the launch of AI-powered software - Lichen AI Robot, which was developed on GPT-based technology.</li>
<li>UroGen Pharma Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/urgn#NASDAQ">URGN</a>) rose 11.1% to $17.51.</li>
<li>Cazoo Group Ltd (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/czoo#NASDAQ">CZOO</a>) gained 11% to $4.12 after declining around 21% on Friday.</li>
<li>Salarius Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/slrx#NASDAQ">SLRX</a>) rose 10.5% to $0.6849 following fourth-quarter results.</li>
<li>MicroStrategy Incorporated (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mstr#NASDAQ">MSTR</a>) gained 10.3% to $1,680.00 amid strength in Bitcoin.</li>
<li>Masimo Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/masi#NASDAQ">MASI</a>) jumped 9.5% to $147.72 after the company announced it has authorized management to evaluate a proposed separation of its consumer business.</li>
<li>Foot Locker, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/fl#NYSE">FL</a>) shares rose 8.4% to $26.45 after Evercore ISI Group upgraded the stock from In-Line to Outperform and raised its price target from $28 to $32.</li>
<li>GameStop Corp. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/gme#NYSE">GME</a>) gained 8.2% to $14.17.</li>
<li>Esperion Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/espr#NASDAQ">ESPR</a>) gained 6.6% to $2.40 after the FDA approved broad labels for NEXLETOL and NEXLIZET to prevent heart attacks and cardiovascular procedures, regardless of statin use.</li>
<li>Micron Technology, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mu#NASDAQ">MU</a>) climbed 5.1% to $115.81.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>Sintx Technologies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sint#NASDAQ">SINT</a>) shares fell 49.1% to $0.0471 after the company announced pricing of a $1.3 million public offering of common stock.</li>
<li>Akanda Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/akan#NASDAQ">AKAN</a>) fell 38.1% to $0.1507 after the company announced pricing of underwritten public offering.</li>
<li>Fisker Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/fsr#NYSE">FSR</a>) dipped 28.1% to $0.0897 after the company announced it received notice from the large automaker with which the company had been in negotiations for a potential transaction that the automaker terminated the negotiations.</li>
<li>Australian Oilseeds Holdings Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/coot#NASDAQ">COOT</a>) fell 25.4% to $1.85 after falling over 22% on Friday.</li>
<li>Vimeo, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vmeo#NASDAQ">VMEO</a>)&nbsp;fell 26% to $3.98.</li>
<li>Aurora Mobile Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/jg#NASDAQ">JG</a>) dipped 18.8% to $2.8428. Aurora Mobile announced plans to use Moonshot AI large language model in its AI bot creation platform, GPTBots.AI.</li>
<li>Invivyd, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ivvd#NASDAQ">IVVD</a>) fell 18.3% to $3.56. Invivyd shares jumped 41% on Friday after the company announced that PEMGARDA received emergency use authorization from the FDA for the pre-exposure prophylaxis of COVID-19.</li>
<li>Li-Cycle Holdings Corp. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/licy#NYSE">LICY</a>) dipped 18.7% to $0.9181.</li>
<li>Aehr Test Systems (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aehr#NASDAQ">AEHR</a>) fell 18.1% to $12.01 after the company reported preliminary third-quarter and FY24 adjusted EPS and revenue results below estimates.</li>
<li>Bitcoin Depot Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/btm#NASDAQ">BTM</a>) fell 17.1% to $2.2216 following weak quarterly sales.</li>
<li>Invivyd, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ivvd#NASDAQ">IVVD</a>) declined 16.7% to $3.63.</li>
<li>Sonder Holdings Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sond#NASDAQ">SOND</a>) fell 16.3% to $3.29.</li>
<li>Jowell Global Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/jwel#NASDAQ">JWEL</a>) fell 16.1% to $1.36.</li>
<li>BYND Cannasoft Enterprises Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bcan#NASDAQ">BCAN</a>) fell 15.4% to $2.12 after dipping 31% on Friday.</li>
<li>Canopy Growth Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cgc#NASDAQ">CGC</a>) fell 13.1% to $6.68. The German government recently approved legislation which legalizes the possession and cultivation of cannabis beginning April 1.</li>
<li>Compass Minerals International, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cmp#NYSE">CMP</a>) declined 13.1% to $15.25. US Forest Service halted contract with Compass Minerals for 2024 Fire Season due to safety concerns.</li>
<li>Yiren Digital Ltd. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/yrd#NYSE">YRD</a>) fell 12% to $4.46.</li>
<li>Dyne Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dyn#NASDAQ">DYN</a>) dipped 11.8% to $24.90 after the company announced a CEO transition.</li>
<li>Open Lending Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lpro#NASDAQ">LPRO</a>) fell 10.3% to $6.41. Open Lending named Chuck Jehl as COO and Interim CEO.</li>
<li>Ontrak, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/otrk#NASDAQ">OTRK</a>) fell 10% to $0.3531 after jumping around 50% on Friday.</li>
<li>Laser Photonics Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lase#NASDAQ">LASE</a>) shares fell 9.2% to $1.68 after dipping around 9% on Friday. Laser Photonics, last week, announced a distribution agreement with Incredible Supply &amp; Logistics (ISL) for its military and industrial laser solutions.</li>
<li>OKYO Pharma Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/okyo#NASDAQ">OKYO</a>) shares fell 7.5% to $1.42 after falling around 13% on Friday. OKYO Pharma, last week, announced additional key findings from analyses of the clinical data set from the 240-patient Phase 2 trial evaluating the safety and efficacy of OK-101 (0.05%) ophthalmic solution in patients with dry eye disease (DED).</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/markets/cryptocurrency/24/03/37913851/bitcoin-surpasses-67-000-internet-computer-emerges-as-top-gainer"> Bitcoin Surpasses $67,000; Internet Computer Emerges As Top Gainer</a>

ABBV

AEHR

BCLI

CIFR

COOT

CYTO

CZOO

FRGE

GDRX

IVVD

JWEL

LABP

LASE

LCID

LDOS

LICN

LICY

LPRO

MASI

MLGO

NKTX

OKYO

OTRK

SGMT

SLRX

SOND

STIM

SWVL

URGN

VMEO

XTLB

Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day Session

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Esperion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESPR#NASDAQ">ESPR</a>) with a Buy and maintains $16 price target.

HC Wainwright & Co. Reiterates Buy on Esperion Therapeutics, Maintains $16 Price Target

Friday, the FDA approved broad new label expansions for&nbsp;Esperion Therapeutics Inc&#8217;s&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESPR#NASDAQ">ESPR</a>) NEXLETOL (bempedoic acid) Tablets and NEXLIZET (bempedoic acid and ezetimibe) Tablets based on CLEAR Outcomes data that include indications for cardiovascular risk reduction and expanded LDL-C lowering in primary and&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/03/g37898499/u-s-fda-approves-broad-new-labels-for-nexletol-and-nexlizet-to-prevent-heart-attacks-and-cardiovas" rel="noreferrer noopener">secondary prevention patients</a>.&nbsp;
In addition, the enhanced labels support using NEXLETOL and NEXLIZET alone or in combination with statins.&nbsp;
They also include new indications for primary hyperlipidemia, alone or in combination with a statin, and are the only LDL-C lowering non-statin drugs indicated for primary prevention patients.
NEXLETOL/NEXLIZET is indicated as an adjunct to diet and statin therapy for primary hyperlipidemia (lower lipids in the blood) in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.
&#8220;We are pleased to receive approval for our highly anticipated label expansions in the U.S., which will enable more than 70 million patients to now be eligible for NEXLETOL and NEXLIZET,&#8221; said Sheldon Koenig, President and CEO.&nbsp;
The company&#8217;s pending label expansions in Europe remain on track, with a positive opinion from the Committee for Medicinal Products for Human Use. The company anticipates a final determination by the European Medicines Agency in&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/03/g37893418/chmp-issues-positive-opinions-for-both-bempedoic-acid-and-the-bempedoic-acid-ezetimibe-fixed-dose-" rel="noreferrer noopener">the second quarter of 2024</a>.
The U.S. approvals of NEXLIZET and NEXLETOL for cardiovascular risk reduction and LDL-C lowering were based on data generated from the CLEAR Outcomes trial, assessing the effect of NEXLETOL on cardiovascular outcomes in nearly 14,000 patients with, or at high risk, of cardiovascular disease.&nbsp;
In the study, LDL-C was reduced by 20%, hsCRP was reduced by 22%, and glucose was not elevated by bempedoic acid compared to placebo.&nbsp;
Patients who received bempedoic acid in the trial experienced a relative risk reduction of:
<ul>
<li>15% for MACE-3 (death from a cardiovascular cause, nonfatal stroke, or nonfatal myocardial infarction)</li>
<li>&nbsp;27% for nonfatal myocardial infarction</li>
<li>&nbsp;19% for coronary revascularization</li>
<li>&nbsp;39% for MACE-3 in primary prevention patients</li>
</ul>
Price Action: ESPR shares are up 19.6% at $2.73 during the premarket session on the last check Monday.
Illustration of Phrama lab worker created with MidJourney.

Equities

Health Care

Why Is Heart Disease-Focused Esperion Therapeutics Stock Trading Higher On Monday?

<h3>Gainers</h3>
<ul>
<li>Landos Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LABP#NASDAQ">LABP</a>) shares moved upwards by 181.6% to $22.05 during Monday's pre-market session. The market value of their outstanding shares is at $68.7 million. As per the press release, Q4 earnings came out 2 days ago. </li>
<li>Altamira Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTO#NASDAQ">CYTO</a>) shares rose 49.71% to $2.59. The market value of their outstanding shares is at $4.7 million. </li>
<li>Esperion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESPR#NASDAQ">ESPR</a>) stock increased by 21.83% to $2.79. The company's market cap stands at $516.2 million. </li>
<li>Salarius Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLRX#NASDAQ">SLRX</a>) shares moved upwards by 21.66% to $0.75. The company's market cap stands at $2.9 million. As per the news, the Q4 earnings report came out yesterday. </li>
<li>Neuronetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STIM#NASDAQ">STIM</a>) stock increased by 18.19% to $5.0. The market value of their outstanding shares is at $148.7 million. </li>
<li>Nkarta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTX#NASDAQ">NKTX</a>) stock rose 17.93% to $10.52. The market value of their outstanding shares is at $516.2 million. As per the news, the Q4 earnings report came out 2 days ago. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>SINTX Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SINT#NASDAQ">SINT</a>) stock declined by 46.5% to $0.05 during Monday's pre-market session. </li>
<li>Akanda (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKAN#NASDAQ">AKAN</a>) stock declined by 32.2% to $0.17. The market value of their outstanding shares is at $1.4 million. </li>
<li>Trxade Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEDS#NASDAQ">MEDS</a>) stock declined by 30.42% to $16.75. The market value of their outstanding shares is at $20.1 million. </li>
<li>Nuvation Bio (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUVB#NYSE">NUVB</a>) shares declined by 18.62% to $1.88. The company's market cap stands at $411.8 million. </li>
<li>Yield10 Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YTEN#NASDAQ">YTEN</a>) stock fell 11.82% to $0.33. The market value of their outstanding shares is at $3.9 million. </li>
<li>Virios Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIRI#NASDAQ">VIRI</a>) stock declined by 9.27% to $0.41. The market value of their outstanding shares is at $7.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

MEDS

NUVB

VIRI

YTEN

12 Health Care Stocks Moving In Monday's Pre-Market Session

MLGO: 102% &#x7C;&nbsp;<a href="https://www.benzinga.com//node/37911190">MicroAlgo Inc. Announced a Deep Clustering Algorithm Based on Multi-level Feature Fusion</a>
MASI: 15% &#x7C;&nbsp;<a href="https://www.benzinga.com//node/37910707">Masmi shares are trading higher after the company announced it has authorized management to evaluate a proposed separation of its consumer business.</a>
ESPR: 26% &#x7C;&nbsp;<a href="https://www.benzinga.com//node/37909794">Esperion shares are trading higher after the FDA approved broad labels for NEXLETOL and NEXLIZET to prevent heart attacks and cardiovascular procedures, regardless of statin use.</a>

Market-Moving News for March 25th

Shares of Salarius Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/slrx#NASDAQ">SLRX</a>) rose sharply in today&rsquo;s pre-market trading <a href="https://www.benzinga.com/quote/SLRX/earnings">following fourth-quarter results.</a>
Salarius Pharmaceuticals posted a net loss of $0.9 million, or 22 cents per share for the fourth quarter, narrower than the year-ago loss of $6.4 million, or $2.83 per share, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Salarius Pharmaceuticals shares jumped 31.4% to $0.8149 in pre-market trading
Here are some other stocks moving in pre-market trading.
<h3>Gainers</h3>
<ul>
<li>Next.e.GO N.V. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/egox#NASDAQ">EGOX</a>) shares rose 85.8% to $0.0730 in pre-market trading after falling around 22% on Friday.</li>
<li>MicroAlgo Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mlgo#NASDAQ">MLGO</a>) rose 56.7% to $6.30 in pre-market trading after declining around 5% on Friday.</li>
<li>Forge Global Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/frge#NYSE">FRGE</a>) shares gained 22.8% to $2.86 in pre-market trading after gaining 13% on Friday.</li>
<li>Canopy Growth Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cgc#NASDAQ">CGC</a>) gained 19.5% to $9.17 in pre-market trading. The German government approved legislation which legalizes the possession and cultivation of cannabis beginning April 1.</li>
<li>Flora Growth Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/flgc#NASDAQ">FLGC</a>) shares rose 17.7% to $1.86 in pre-market trading after surging around 34% on Friday.</li>
<li>Cazoo Group Ltd (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/czoo#NASDAQ">CZOO</a>) gained 17.3% to $4.35 in pre-market trading after declining around 21% on Friday.</li>
<li>Biophytis S.A. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bpts#NASDAQ">BPTS</a>) climbed 17.1% to $0.4471 in pre-market trading. Biophytis recently presented its Phase 3 protocol of RuvembriTM in the treatment of Sarcopenia at the ICFSR.</li>
<li>Recon Technology, Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rcon#NASDAQ">RCON</a>) shares rose 14.5% to $0.1570 in pre-market trading.</li>
<li>Esperion Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/espr#NASDAQ">ESPR</a>) gained 12.7% to $2.58 in pre-market trading as the U.S. FDA approved broad new labels for Esperion&#39;s NEXLETOL&reg; and NEXLIZET&reg; to prevent heart attacks and cardiovascular procedures in both primary and secondary prevention patients, regardless of statin use.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>Sintx Technologies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sint#NASDAQ">SINT</a>) dipped 29.7% to $0.0650 in pre-market trading. SINTX Technologies shares dipped 32% on Friday after the company announced a proposed public offering of common stock.</li>
<li>Invivyd, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ivvd#NASDAQ">IVVD</a>) declined 14.8% to $3.72 in pre-market trading. Invivyd shares jumped 41% on Friday after the company announced that PEMGARDA received emergency use authorization from the FDA for the pre-exposure prophylaxis of COVID-19.</li>
<li>Greenlane Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gnln#NASDAQ">GNLN</a>) fell 10.8% to $0.52 pre-market trading after jumping around 11% on Friday.</li>
<li>BYND Cannasoft Enterprises Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bcan#NASDAQ">BCAN</a>) fell 10.8% to $2.24 pre-market trading after dipping 31% on Friday.</li>
<li>Mangoceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mgrx#NASDAQ">MGRX</a>) shares tumbled 9.7% to $0.1688 in pre-market trading after declining around 5% on Friday.</li>
<li>Australian Oilseeds Holdings Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/coot#NASDAQ">COOT</a>) fell 8.5% to $2.27 in pre-market trading after falling over 22% on Friday.</li>
<li>Ontrak, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/otrk#NASDAQ">OTRK</a>) fell 8.2% to $0.36 in pre-market trading after jumping around 50% on Friday.</li>
<li>Murano Global Investments Plc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mrno#NASDAQ">MRNO</a>) shares fell 7.6% to $19.64 in pre-market trading amid volatility following the company&#39;s recently completed business combination with HCM Acquisition Corp and Nasdaq debut last week.</li>
<li>Laser Photonics Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lase#NASDAQ">LASE</a>) shares fell 6.5% to $1.73 in pre-market trading after dipping around 9% on Friday. Laser Photonics, last week, announced a distribution agreement with Incredible Supply &amp; Logistics (ISL) for its military and industrial laser solutions.</li>
<li>OKYO Pharma Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/okyo#NASDAQ">OKYO</a>) shares tumbled 6.2% to $1.44 after falling around 13% on Friday. OKYO Pharma, last week, announced additional key findings from analyses of the clinical data set from the 240-patient Phase 2 trial evaluating the safety and efficacy of OK-101 (0.05%) ophthalmic solution in patients with dry eye disease (DED).</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/news/24/03/37889754/top-5-consumer-stocks-that-may-crash-this-month"> Top 5 Consumer Stocks That May Crash This Month</a>

BPTS

GNLN

MGRX

RCON

Why Salarius Pharmaceuticals Shares Are Trading Higher By Around 31%; Here Are 20 Stocks Moving Premarket

Esperion shares are trading higher after the FDA approved broad labels for NEXLETOL and NEXLIZET to prevent heart attacks and cardiovascular procedures, regardless of statin use.

U.S. stock futures were lower this morning, with the Dow futures falling by around 50 points on Monday.
Shares of Esperion Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/espr#NASDAQ">ESPR</a>) rose sharply in&nbsp;today&rsquo;s pre-market trading.
The U.S. FDA approved broad new labels for Esperion&#39;s NEXLETOL&reg; and NEXLIZET&reg; to prevent heart attacks and cardiovascular procedures in both primary and secondary <a href="https://www.benzinga.com/quote/ESPR">prevention patients, regardless of statin use</a>.
Esperion Therapeutics shares jumped 12.7% to $2.58 in pre-market trading.
Here are some big stocks recording gains in today&rsquo;s pre-market trading session.
<ul>
<li>Forge Global Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/frge#NYSE">FRGE</a>) shares gained 22.8% to $2.86 in pre-market trading after gaining 13% on Friday.</li>
<li>Canopy Growth Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cgc#NASDAQ">CGC</a>) gained 19.5% to $9.17 in pre-market trading. The German government approved legislation which legalizes the possession and cultivation of cannabis beginning April 1.</li>
<li>Masimo Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/masi#NASDAQ">MASI</a>) shares climbed 13.8% to $153.65 in pre-market trading after the company announced it has authorized management to evaluate a proposed separation of its consumer business. The company also reaffirmed its first-quarter and FY24 guidance.</li>
<li>Cronos Group Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cron#NASDAQ">CRON</a>) rose 9.6% to $2.86 in pre-market trading after gaining 9% on Friday.</li>
<li>Nuvation Bio Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nuvb#NASDAQ">NUVB</a>) gained 8.2% to $2.50 in pre-market trading after gaining 3% on Friday.</li>
<li>Tilray Brands, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tlry#NASDAQ">TLRY</a>) gained 5.2% to $2.43 in pre-market trading after jumping 18% on Friday. Germany approved the legalization of cannabis for adult use.</li>
<li>WK Kellogg Co (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/klg#NYSE">KLG</a>) rose 4.8% to $19.49 in pre-market trading.</li>
<li>GoodRx Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gdrx#NASDAQ">GDRX</a>) shares climbed 4.1% to $6.85 in pre-market trading. Wells Fargo analyst Stan Berenshteyn upgraded GoodRx from Equal-Weight to Overweight and announced a $10 price target.</li>
<li>Century Aluminum Company (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cenx#NASDAQ">CENX</a>) shares gained 3.6% to $13.69 in pre-market trading.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/news/earnings/24/03/37885621/investor-optimism-improves-slightly-dow-jumps-over-250-points"> Investor Optimism Improves Slightly; Dow Jumps Over 250 Points </a>
Don&rsquo;t forget to check out our <a href="https://www.benzinga.com/premarket/"> premarket coverage here </a>

CENX

CRON

Esperion Therapeutics, Masimo And Other Big Stocks Moving Higher In Monday's Pre-Market Session